Emergent BioSolutions Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Emergent BioSolutions Inc. on April 30, 2025. The filing was dated May 6, 2025, and signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer, and Treasurer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, 36,140,808 shares were present or represented by proxy, representing approximately 67% of the 54,337,026 outstanding shares entitled to vote. Three proposals were considered:
- Proposal 1 (Director Election): All three Class I director nominees were elected.
- Keith Katkin: 21,684,528 For; 1,094,567 Withhold.
- Ronald Richard: 18,116,845 For; 4,662,250 Withhold.
- Kathryn Zoon, Ph.D.: 21,779,200 For; 999,895 Withhold.
- Proposal 2 (Auditor Ratification): Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025 was approved.
- For: 34,773,959; Against: 1,152,704; Abstentions: 214,145.
- Proposal 3 (Executive Compensation): Advisory approval of 2024 named executive officer compensation was approved.
- For: 18,928,777; Against: 3,537,501; Abstentions: 312,817.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the full voting breakdown for Director Ronald Richard, who received a higher number of "Withhold" votes compared to other nominees.
- Review the definitive proxy statement on Schedule 14A (filed March 21, 2025) for detailed biographies of elected directors and executive compensation specifics.
- Confirm the record date of March 3, 2025, for share ownership eligibility.